Available

sale investments at

, and were

million and

million, respectively. The fair value of the Company’s investment in ChemoCentryx, Inc (CCXI) decreased million from at to million at The remaining decrease was caused by the maturities of

million in corporate bond securities held by Advanced Cell Diagnostics (ACD) and

million in certificate of deposits held in China. The cost basis of the Company's investment in CCXI at and was million.

Inventories:

 

 

Property and Equipment:

 

Intangible Assets:

months ended consist of (in thousands):

is as follows (in thousands):

 

Goodwill:

months ended consist of (in thousands):

fourth

le impairment. The Company performed a quantitative assessment for all of its reporting units during the quarter of fiscal year The quantitative assessment indicated that all of the reporting units had substantial headroom as of

No

were identified during the quarter ended There has been impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC guidance for goodwill and other intangibles on

 

Other Assets:

her Assets consist of (in thousands):

the Company had million of other assets compared to

million as of Investments include a

million investment in Astute Medical, Inc

. made during the quarter of fiscal year This investment is accounted for under the cost-method as we own less than of the outstanding stock and we concluded that we do have significant influence. Under the cost-method, the fair value is estimated if there are identified events or changes in circumstances that have a significant adverse effect on the fair value of the investment. such events or changes in circumstances were identified in the period ended

.